Arcutis Biotherapeutics, Inc. Common Stock (ARQT) is a publicly traded Healthcare sector company. As of August 24, 2026, ARQT trades at $24.77 with a market cap of $3.15B and a P/E ratio of 117.95. ARQT moved -1.24% today. Year to date, ARQT is -13.64%; over the trailing twelve months it is +58.83%. Its 52-week range spans $11.13 to $31.77. Analyst consensus is strong buy with an average price target of $36.57. Rallies surfaces ARQT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for ARQT shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $24.77 |
| Market Cap | $3.15B |
| P/E Ratio | 117.95 |
| EPS | $0.21 |
| Dividend Yield | 0.00% |
| 52-Week High | $31.77 |
| 52-Week Low | $11.13 |
| Volume | 834.68K |
| Avg Volume | 0 |
| Revenue (TTM) | $463.98M |
| Net Income | $28.52M |
| Gross Margin | 91.14% |
7 analysts cover ARQT: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $36.57.